Insmed’s ENCORE Trial Reaches Key Milestone in MAC Lung Infection
Insmed (INSM) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: Insmed’s ENCORE trial (NCT04677569) is a phase 3 study testing whether adding ALIS (amikacin liposome inhalation suspension) to standard oral therapy can better relieve symptoms in adults with newly diagnosed nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC). The focus is on how patients feel and breathe after 13 months of treatment, which is important because this hard-to-treat lung disease often leads to chronic symptoms and high healthcare use.
Intervention/Treatment: The study compares two regimens. The test group receives ALIS, an inhaled antibiotic (marketed as ARIKAYCE), once a day alongside standard oral drugs azithromycin and ethambutol. The control group receives a matching placebo inhalation (empty liposome control) plus the same oral background treatment. The goal is to see if the ALIS-based combination offers better symptom relief and safety than standard therapy alone.
Study Design: ENCORE is an interventional, randomized trial. Participants are randomly assigned to one of the two treatment arms, which run in parallel. The study is double-blind, meaning neither patients nor investigators know who receives ALIS or placebo, reducing bias. The primary purpose is treatment, with the main outcome based on patient-reported respiratory symptoms rather than only lab or imaging results.
Study Timeline: The trial was first submitted in December 2020, marking the formal start of regulatory tracking. The overall status is now listed as completed, indicating treatment and primary data collection are finished. The primary completion date has passed, and full study completion is expected around the same timeframe, covering follow-up and analysis. The most recent update to the record was posted on February 2, 2026, signaling that key data or administrative details have been refreshed, even though formal results are not yet posted.
Market Implications: For investors, this update confirms that Insmed has advanced a major late-stage asset in a niche but serious lung disease. Positive ENCORE results could reinforce or expand ARIKAYCE’s role in MAC lung infection and support longer-term revenue durability, which may be supportive for INSM’s valuation and strengthen management’s case for additional pipeline investment. Conversely, inconclusive or negative symptom data could limit uptake and pricing power. The NTM space has limited direct competition, but broader respiratory and anti-infective players could react if ENCORE shifts treatment guidelines or payer coverage. Until full data are released, investor sentiment is likely to hinge on expectations and any signals from corporate commentary rather than the registry update alone.
The ENCORE study has completed treatment and is recently updated on ClinicalTrials.gov, and further details will be available on the ClinicalTrials portal as results are posted.
To learn more about INSM’s potential, visit the Insmed drug pipeline page.
